General Information of DTT (ID: TTE0A2F)

DTT Name Dopamine D4 receptor (D4R) DTT Info
Gene Name DRD4

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
2 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [1]
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [2]
------------------------------------------------------------------------------------
4 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [3]
L-745,870 DMTGR25 Psychotic disorder 6A20-6A25 Phase 2 [4]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [5]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [6]
------------------------------------------------------------------------------------
8 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABT-724 DMDQVY4 Erectile dysfunction HA01.1 Discontinued in Phase 2 [7]
Lu-35138 DMQ7A35 Psychotic disorder 6A20-6A25 Discontinued in Phase 2 [8]
NGD-94-4 DMZ9WLO Schizophrenia 6A20 Discontinued in Phase 1 [9]
A-80426 DMBC3DG N. A. N. A. Terminated [10]
Belaperidone DMM0ZIJ Schizophrenia 6A20 Terminated [6]
BIMG80 DM9X1DZ Psychotic disorder 6A20-6A25 Terminated [11]
Sonepiprazole DMFI0GW Schizophrenia 6A20 Terminated [6]
YM-43611 DMWI094 Psychotic disorder 6A20-6A25 Terminated [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Discontinued Drug(s)
3 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
PD-165167 DMD0GB4 Schizophrenia 6A20 Preclinical [6]
SPI-376 DMC1WAJ Schizophrenia 6A20 Preclinical [6]
U-99363E DMOIWVC Schizophrenia 6A20 Preclinical [6]
------------------------------------------------------------------------------------
60 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [13]
(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine DMHQCRU Discovery agent N.A. Investigative [14]
(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine DMQM8O5 Discovery agent N.A. Investigative [14]
1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine DMUDVRM Discovery agent N.A. Investigative [15]
1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine DMF0GXD Discovery agent N.A. Investigative [16]
1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine DMBRJ5S Discovery agent N.A. Investigative [16]
1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine DMSBNY8 Discovery agent N.A. Investigative [16]
1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine DMCJZVA Discovery agent N.A. Investigative [16]
1-Benzyl-4-pyrrol-1-yl-piperidine DMNWEC9 Discovery agent N.A. Investigative [16]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 Discovery agent N.A. Investigative [17]
1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine DMTNRG7 Discovery agent N.A. Investigative [2]
1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine DMLSU30 Discovery agent N.A. Investigative [2]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL Discovery agent N.A. Investigative [2]
3-(2-Benzylamino-ethoxy)-phenol DMZCTGF Discovery agent N.A. Investigative [18]
3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole DM0HYDZ Discovery agent N.A. Investigative [19]
3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole DM17SNR Discovery agent N.A. Investigative [19]
3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole DMM0WGI Discovery agent N.A. Investigative [19]
4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one DMYVD2E Discovery agent N.A. Investigative [18]
4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole DMXAEW9 Discovery agent N.A. Investigative [20]
4-(4-Benzyl-piperazin-1-yl)-1H-indole DMWR0AS Discovery agent N.A. Investigative [20]
4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole DMZ4237 Discovery agent N.A. Investigative [20]
4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole DMVAB7U Discovery agent N.A. Investigative [20]
4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine DM08CG7 Discovery agent N.A. Investigative [2]
A-381393 DMI4TVB Discovery agent N.A. Investigative [4]
A-425444 DMM5XD6 Discovery agent N.A. Investigative [21]
A412997 DMKY9G5 Discovery agent N.A. Investigative [22]
ABT-670 DM6J57N Discovery agent N.A. Investigative [21]
Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine DMTC4G0 Discovery agent N.A. Investigative [18]
Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine DMV6DY7 Discovery agent N.A. Investigative [18]
CP-226269 DMGLO2X Discovery agent N.A. Investigative [23]
E-1455 DMHPFMV Schizophrenia 6A20 Investigative [24]
FAUC 113 DMC6J3B Discovery agent N.A. Investigative [25]
FAUC213 DM1LMFG Discovery agent N.A. Investigative [23]
FLUMEZAPINE DMW0HOG Discovery agent N.A. Investigative [26]
FLUTROLINE DMUOHVL Discovery agent N.A. Investigative [27]
ISOCLOZAPINE DM52CPU Discovery agent N.A. Investigative [17]
ISOLOXAPINE DMH1BN4 Discovery agent N.A. Investigative [28]
JL-18 DM0LD3F Discovery agent N.A. Investigative [29]
L-741626 DMCYQJF Discovery agent N.A. Investigative [30]
L-741742 DMP75YK Discovery agent N.A. Investigative [31]
L-750,667 DM2WUKF Discovery agent N.A. Investigative [32]
ML398 DMA0E2Q Discovery agent N.A. Investigative [33]
N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide DMU1ATH Discovery agent N.A. Investigative [34]
N-(4-Propylaminobutyl)-4-biphenylcarboxamide DMG9D7A Discovery agent N.A. Investigative [34]
nafadotride DM79KLR Discovery agent N.A. Investigative [32]
PF-592379 DMY93GJ Discovery agent N.A. Investigative [35]
PG-01037 DM2TP4Q Discovery agent N.A. Investigative [36]
piribedil DMNP6QD Discovery agent N.A. Investigative [37]
QUINPIROLE DMDNHEP Discovery agent N.A. Investigative [38]
RBI257 DM9IQXM Discovery agent N.A. Investigative [23]
Ro 10-4548 DMXT34V Discovery agent N.A. Investigative [23]
SB-271046 DM5VJAF Discovery agent N.A. Investigative [39]
STEPHOLIDINE DMGMXQC Discovery agent N.A. Investigative [40]
TKP-1002 DMZU4O8 Schizophrenia 6A20 Investigative [24]
U101958 DM9GOAV Discovery agent N.A. Investigative [41]
UH-232 DM5K6ZE Discovery agent N.A. Investigative [42]
[125I]L750667 DMO7VRJ Discovery agent N.A. Investigative [43]
[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine DMSPMHE Discovery agent N.A. Investigative [18]
[3H]N-methylspiperone DM5176Y Discovery agent N.A. Investigative [32]
[3H]spiperone DMWHEV8 Discovery agent N.A. Investigative [44]
------------------------------------------------------------------------------------
⏷ Show the Full List of 60 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
4 Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
7 Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
9 I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
10 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
11 BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90.
12 Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 1997 Jul;17(1):27-33.
13 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
14 Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
15 Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9.
16 Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
17 Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
18 New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
19 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
20 New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
21 Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 ago... J Med Chem. 2006 Dec 14;49(25):7450-65.
22 A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol Biochem Behav. 2005 Sep;82(1):140-7.
23 Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 217).
25 Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J Med Chem. 2001 Apr 12;44(8):1151-7.
26 Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
27 Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.
28 Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
29 (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist. J Med Chem. 1996 Jun 21;39(13):2435-7.
30 Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300.
31 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5.
32 Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52.
33 Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity. ACS Med Chem Lett. 2014 Jul 9;5(9):1060-4.
34 Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
35 Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol. 2012 Jun;23(3):280-91.
36 Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
37 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
38 Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of he... J Med Chem. 2005 Sep 8;48(18):5771-9.
39 Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
40 Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
41 Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor. Eur J Pharmacol. 1997 Mar 19;322(2-3):283-6.
42 (Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997).
43 Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol. 1996 Dec;50(6):1658-64.
44 Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors. Neurosci Lett. 1995 Feb 17;186(2-3):145-8.